Table: Solasia Pharma -Q1 group results (IFRS)
15/05/2026 07:39
May 15 (Reuters)-
Solasia Pharma K. K.
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
3 months ended 3 months ended Year to
Mar 31, 2026 Mar 31, 2025 Dec 31, 2026
LATEST YEAR-AGO COMPANY
RESULTS RESULT FORECAST
Sales 6 mln 25 mln
(-75.1 pct) (+111.0 pct)
Operating loss 306 mln loss 296 mln
Pretax loss 306 mln loss 292 mln
Net loss 307 mln loss 292 mln
EPS Basic loss 1.14 yen loss 1.34 yen
EPS Diluted loss 1.14 yen loss 1.34 yen
Ann Div NIL NIL
-Q2 Div NIL NIL
-Q4 Div NIL NIL
NOTE - Solasia Pharma K. K..
(Figures are reported based on international accounting rules (IFRS).)
If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half
dividend and Q4 to the second-half dividend announced before a new corporate law in
2006 allowed companies to pay and report dividends on a quarterly basis.
*Net - represents Net profit attributable to owners of the parent company.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4597.T